Among registrations of peripheral vascular interventional devices, transfemoral arterial balloon catheters are commonly seen yet prone to erroneous judgments at the early project stage. Many project teams get stuck not due to poor document drafting capability, but ambiguous product definition, insufficient grounds for predicate-based clinical evaluation, and improper adoption of identical registration rules for plain balloons and drug-coated balloons. Any wrong decision on the registration pathway will lead to increased workload for subsequent testing, clinical work, supplementary submissions and prolonged time-to-market.

Based on the current Classification Catalogue, Technical Guidelines for Clinical Evaluation of Medical Devices, review specifications for balloon dilatation catheters and the latest regulatory documents for drug-coated balloons, this article sorts out core registration issues of transfemoral arterial balloon catheters, including classification confirmation for Class III registration, applicable scenarios of predicate-based clinical evaluation, circumstances requiring clinical trials, and key evidence to be prepared in advance for technical review.

For such products, "transfemoral artery" only describes access route instead of serving as an independent classification basis. Regulatory classification is determined by intended use, working principle, structural design and indications. When developing balloon dilatation catheter products, teams shall not classify items merely by the term "balloon catheter" or vascular access.

Plain balloons, cutting balloons and other structurally modified balloons, as well as drug-coated balloons differ drastically in clinical evaluation pathways and review priorities. Especially for products with drug coating, special surface treatment, customized balloon structure or expanded indications, applicants shall reassess registration feasibility instead of following conventional catheter development routines.

Early finalized product definition facilitates consistent formulation of product technical requirements, testing schemes, clinical evaluation and registration dossiers. In contrast, ambiguous preliminary definition usually results in repeated revisions of indication descriptions, specification scopes, evaluation strategies and review responses.

A prevalent misunderstanding in transfemoral artery balloon catheter projects is equating clinical trial exemption with simplified clinical evaluation. In fact, exemption from registration clinical trials does not eliminate the requirement for medical device clinical evaluation. The core concern lies in whether complete evidence verifying the product’s safety, performance and clinical benefits can be provided.

Conventional balloon dilatation catheters with mature technical foundations may adopt the predicate-based clinical evaluation pathway if appropriate marketed predicate devices are available and full equivalence demonstration is established covering intended use, composition, critical performance, material biocompatibility, sterilization method, specification range and risk management.

However, clinical trials will be required when matching predicate products are unavailable, discrepancies cannot be fully justified, or products feature innovative structures, drug-device combinations or substantially expanded indications. Instead of picking a preferred pathway arbitrarily at the early stage, project teams shall formulate an assessment table listing product discrepancies, associated risks and corresponding supplementary evidence solutions in advance.

For conventional balloon dilatation catheters, pathway assessment centers on equivalence verification, performance studies and defined indications. Nevertheless, registration rules for drug-coated balloons cannot follow those of plain balloons simply. Drug coating brings disparities in materials and manufacturing processes, along with complicated assessment requirements concerning drug release, local and systemic drug exposure, particle shedding and long-term follow-up.

Separate clinical strategies are required for peripheral drug-coated balloons targeting distinct vascular segments and lesion conditions. Significant divergences exist in clinical endpoints, subject profiles, follow-up standards and evidence extrapolation limits among femoropopliteal artery, infra-popliteal artery and dialysis access applications. Clear early classification of indications helps reduce risks in trial design and regulatory communication.

Accordingly, products coated with paclitaxel, sirolimus or other pharmaceuticals or those intending to reference overseas clinical data need independent preliminary clinical planning rather than late-stage dossier revision. Delayed identification of inappropriate evaluation pathways triggers cascading extensions in project timeline and expenditure.

First, clear definition of product technical requirements and specification scope. Review of balloon catheters covers far more than dilatation performance; regulators examine applicable vessel diameter, lesion length, catheter effective working length, balloon performance limits, indication wording and logical consistency among model specifications. Early formulation of technical requirements ensures consistent documentation preparation afterwards.

Second, sufficiency of performance tests and simulated-use data to reflect clinical applications. Basic tests include dimensional inspection, leak tightness, rated burst pressure and fatigue resistance. Simulated-use testing gains greater significance for products requiring challenging anatomical trackability, accurate positioning and stable delivery. For peripheral interventional devices, test design aligned with real clinical scenarios outweighs mere completion of test items.

Third, complete documentation covering raw materials, biocompatibility, sterilization and shelf-life validation. As Class III devices, balloon dilatation catheters require synchronized planning for material characterization, biological assessment, sterilization residue control and real-time ageing verification right after registration pathway confirmation instead of ad-hoc supplementation later.

Fourth, coating evaluation goes beyond simple confirmation of successful coating application. Vascular devices with hydrophilic lubricious coatings need supporting data on coating composition, intactness and acceptable particle detachment. Drug-coated balloons demand systematic assessment based on drug and excipient properties, in-vivo drug release profile and potential risks of particulate embolism.

First, finalize product definition at an early stage, clarifying whether it is a conventional PTA balloon, drug-coated balloon or balloon with special structural design, as well as specifications for access route, target vessel, lesion type and intended use. Early confirmation avoids repeated revisions in predicate-based clinical evaluation, testing scheme and clinical protocol.

Second, compile review-ready evidence chain for predicate evaluation instead of merely formal comparison tables. Uncertainties in review are reduced not by abundant comparison items, but by full elaboration of product discrepancies, complete risk identification and supplementary tests directly corresponding to identified differences.

Third, arrange regulatory consultation and pathway adjustment prior to key milestones. Projects with ambiguous definition and prominent product differences face tough late modification, especially for drug-coated balloons, devices with special surface treatment, products for unique indications or those adopting overseas clinical data, which require early registration pathway review, clinical evaluation planning and anticipated review risk assessment.

For transfemoral artery balloon catheter projects, Deda Medical delivers comprehensive front-end collaborative services covering registration route definition, clinical evaluation and review support beyond simple document drafting. Customized services include Class III device registration pathway analysis, predicate-based clinical evaluation assistance, clinical trial strategy formulation, drafting of product technical requirements, anticipated review queries and consultation support.

For projects under initiation, classification confirmation, clinical evaluation planning or supplementary document preparation, clarification of product definition, differentiation points and evidence chain is recommended prior to final documentation and trial execution. Early rationalized planning for such Class III interventional devices effectively controls subsequent development cycle and overall costs.

The difficulty in registering transfemoral artery balloon catheters rarely lies in confirming Class III classification, but in identifying divergent registration pathways at an early stage. Conventional balloons, drug-coated balloons and specially structured balloons differ markedly in clinical evaluation, predicate evaluation, clinical trial arrangement and dossier compilation for technical review. Definable registration pathways can only be finalized upon confirmation of product scope, subdivided indications and complete evidence logic.

Deda Medical provides tailored refined registration analysis based on specific product design, indications and existing evidence for clients needing pathway confirmation, compilation of product technical specifications, clinical evaluation framework and regulatory consultation planning. Final submission strategies shall be further assessed against actual product configuration and latest official regulatory documents.

This document is compiled based on published NMPA regulations for reference only. Final registration plans shall be formulated in line with individual product features and updated regulatory requirements, with adequate official communication arranged at key project phases.